YOLFTbeta
Enliven Therapeutics Inc.

Enliven Therapeutics Inc.

ELVN · NASDAQ · Healthcare / Biotechnology

48.80USD+0.49 (+1.01%)

Price History

Full chart

Market Stats

Previous Close48.31
Open48.22
Day Range46.96 – 49.13
52-Week Range14.79 – 62.32
Volume972.57K
Market Cap3.28B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.65
Dividend Yield0.00%
Beta0.24
50-Day Avg55.89
200-Day Avg39.60

About

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Richard A. Fair M.B.A.
  • Employees67
  • Headquarters6200 Lookout Road, Boulder, CO, United States, 80301, USA
  • Websitehttps://www.enliventherapeutics.com

Leadership

  • Mr. Richard A. Fair M.B.A.CEO, President & Director · b. 1969
  • Mr. Samuel S. Kintz M.B.A.Co-Founder & Head of Pipeline · b. 1986
  • Mr. Benjamin HohlCFO & Head of Corporate Development · b. 1989
  • Dr. Helen Louise Collins M.D.Chief Medical Officer · b. 1963
  • Dr. Joseph P. Lyssikatos Ph.D.Co-Founder & Research Fellow · b. 1965
  • Mr. Anish Patel Pharm.D.Co-Founder & COO · b. 1981
  • Dr. Galya D. Blachman Esq., Ph.D.Chief Legal Officer & Head of Business Development · b. 1977
  • Damiette SmitVice President of Clinical Development

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---000000
Cost of Revenue--33.00K97.00K99.00K622.00K297.00K317.00K263.00K
Gross Profit---33.00K-97.00K-99.00K-622.00K-297.00K-317.00K-263.00K
Operating Expense--24.08M9.22M24.66M38.17M83.23M104.24M119.39M
Operating Income-8.90M-10.68M-24.12M-9.32M-24.76M-38.79M-83.53M-104.55M-119.66M
EBITDA221.00K-11.34M-23.43M-9.27M-24.63M-37.45M-71.29M-88.47M-103.43M
Net Income--11.34M-23.46M-18.97M-24.74M-37.66M-71.58M-89.02M-103.69M
R&D7.92M8.24M19.01M8.24M20.47M31.02M64.57M80.78M85.86M
Interest Expense----93.00K1.22M---

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets10.22M7.71M33.30M90.84M113.33M83.30M271.87M325.76M476.17M
Total Liabilities1.49M1.83M4.38M6.41M6.47M160.12M25.96M15.91M16.68M
Total Equity-15.53M-26.32M-48.85M84.44M106.86M-76.83M245.91M309.85M459.60M
Cash9.67M7.38M4.94M47.70M110.02M75.54M100.14M124.12M98.90M
Total Debt660.00K--105.00K159.00K323.00K335.00K-399.00K
Net Debt-9.01M-7.38M-4.94M-47.70M-109.86M-75.21M-99.81M-124.12M-98.50M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-8.79M-8.78M-21.88M-8.53M-19.13M-32.08M-61.27M-73.19M-70.30M
Investing Cash Flow---24.06M-461.00K-191.00K-612.00K-148.41M-36.00M-173.84M
Financing Cash Flow11.00M6.49M43.58M130.51M-1.02M-1.80M234.29M133.16M218.87M
Capital Expenditure00140.00K461.00K191.00K612.00K149.00K44.00K158.00K
Free Cash Flow-8.79M-8.78M-22.02M-8.99M-19.32M-32.69M-61.42M-73.24M-70.46M
FCF to OCF100.00%100.00%100.64%105.41%101.00%101.91%100.24%100.06%100.22%

Earnings

Report DateOct 8, 2019Mar 11, 2020May 7, 2020Aug 14, 2020Nov 5, 2020Mar 5, 2021May 11, 2021Aug 6, 2021Nov 9, 2021Mar 15, 2022May 6, 2022Aug 3, 2022Oct 25, 2022Feb 10, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 14, 2024May 14, 2024Aug 13, 2024Nov 13, 2024Mar 12, 2025May 14, 2025Aug 13, 2025Nov 12, 2025Mar 12, 2026May 7, 2026Aug 5, 2026Nov 11, 2026
EPS Estimate0.000.00-2.94-2.25-3.21-3.35-3.34-3.20-3.38-3.00-2.31-2.05-1.00-0.79-0.52-0.40-0.47-0.54-0.57-0.56-0.50-0.52-0.50-0.42-0.46-0.38-0.41-0.38-0.43
EPS Actual-0.32-0.68-17.24-2.36-2.88-2.24-2.32-2.96-2.20-2.12-2.24-1.76-0.721.21-0.80-0.41-0.51-0.47-0.54-0.41-0.48-0.46-0.57-0.49-0.32-0.48-0.38-0.49-
Surprise---486.39%-4.89%10.28%33.13%30.54%7.50%34.91%29.33%3.03%14.15%28.00%253.94%-53.85%-2.50%-8.51%12.96%5.26%26.79%4.00%11.11%-14.00%-16.67%30.43%-27.05%7.32%-28.95%-
Timing-After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap3.28B
Enterprise Value2.48B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.77
EPS-1.65
Book Value12.22
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-124.28M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-15.31%
Return on Assets-11.00%
Shares Outstanding73.27M
Shares Float60.52M
Beta0.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 73.90
  • Strong Buy
    7
  • Buy
    1

Ownership Breakdown

Institutions
114.02%
Insiders
6.22%
Retail / Other
0.00%

Top Institutional Holders

  • Orbimed Advisors LLC
    7.96M10.86%
  • FMR Inc
    6.83M9.32%
  • Polar Capital Holdings PLC
    5.07M6.91%
  • BlackRock Inc
    3.68M5.03%
  • COMMODORE CAPITAL LP
    3.27M4.47%
  • Vestal Point Capital LP
    3.25M4.44%
  • Bellevue Group AG
    2.32M3.17%
  • Vanguard Capital Management, LLC
    2.17M2.96%
  • Citadel Advisors Llc
    2.07M2.82%
  • Fairmount Funds Management LLC
    1.86M2.53%
  • VR Adviser, LLC
    1.73M2.36%
  • First Light Asset Management, LLC
    1.36M1.86%
  • Novo A/S
    1.28M1.75%
  • Pictet Asset Manangement SA
    1.16M1.59%

Top Fund Holders

  • Polar Capital Healthcare Opports Inc
    3.61M4.93%
  • Polar Capital Biotech S Inc
    2.56M3.49%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.89M2.58%
  • Fidelity Small Cap Growth
    1.52M2.07%
  • Fidelity Select Health Care
    1.34M1.83%
  • iShares Russell 2000 ETF
    1.10M1.50%

Stock Splits

  • Feb 24, 20231:4